

KAMRON LABORATORIES LIMITED

[CIN : L24231GJ1988PLC010956]

Regd. Office: Office No. 904, 9th Floor, Shapath-I Complex, Opp. Rajpath Club, Nr. Madhur Hotel,
S. G. Highway, Bodakdev, Ahmedabad – 380 054, Gujarat, India

E-mail : info@kamronlabs.com



KAMRON

13th August, 2019

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

Company Code No. 524604

Dear Sirs,

Sub: Submission of Unaudited Financial Results for the quarter ended on 30th June, 2019

We refer to our letter dated 2nd August, 2019 informing the date of Meeting of the Board of Directors of the Company. Please note that the Board of Directors in their meeting held today, have taken on record the Unaudited Financial Results for the quarter ended on 30th June, 2019.

We are enclosing herewith copy of the said Unaudited Financial Results.

This is as per Regulation – 33 of the SEBI (LODR) Regulations, 2015.

Thanking you,

Yours faithfully,

For KAMRON LABORATORIES LIMITED

Kamlesh J. Laskari

KAMLESH J. LASKARI
MANAGING DIRECTOR



Encl: As above.

KAMRON LABORATORIES LIMITED

[CIN : L24231GJ1988PLC010956]

Regd. Office: Office No. 904, 9th Floor, Shapath-I Complex, Opp. Rajpath Club, Nr. Madhur Hotel,
S. G. Highway, Bodakdev, Ahmedabad – 380 054, Gujarat, India

E-mail : info@kamronlabs.com



KAMRON

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED ON 30TH JUNE, 2019

(Rs. In lakh)

Particulars		3 months ended on			Previous Year ended on 31-03-2019
		30-06-2019	31-03-2019	30-06-2018	
(Refer Notes Below)		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Revenue from operations	158.51	104.84	174.02	559.42
2	Other income	0.51	13.29	0.08	24.89
3	Total Income (1+2)	159.02	118.13	174.10	584.31
4	Expenses				
	a. Cost of Materials consumed	0.63	21.83	63.14	95.76
	b. Purchases of stock-in-trade	88.84	36.65	-	150.56
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	18.09	(199.58)	(16.50)	(103.87)
	d. Employee benefits expense	36.50	30.30	42.76	151.62
	e. Finance costs	0.02	1.65	2.97	7.27
	f. Depreciation & amortisation expense	20.86	18.41	18.35	73.44
	g. Other expenses	54.54	25.32	63.22	206.49
	Total Expenses	219.48	(65.42)	173.94	581.27
5	Profit / (Loss) before exceptional items and tax (3-4)	(60.46)	183.55	0.16	3.04
6	Exceptional items		-	-	-
7	Profit / (Loss) before tax (5-6)	(60.46)	183.55	0.16	3.04
8	Tax expense:				
	Current tax		-	-	-
	Deferred tax		-	-	-
	Earlier Year	-	0.28	-	0.28
9	Profit / (Loss) for the period from continuing operations (7-8)	(60.46)	183.27	0.16	2.76
10	Profit/(loss) from discontinuing operations before Tax		-	-	-
11	Tax expense of discontinuing operations		-	-	-
12	Profit/(loss) from Discontinuing operations (after tax) (10-11)		-	-	-
13	Profit / (Loss) for the period (9+12)	(60.46)	183.27	0.16	2.76



FOR, KAMRON LABORATORIES LTD.

Kamlesh C. Larkar
MANAGING DIRECTOR

KAMRON LABORATORIES LIMITED

[CIN : L24231GJ1988PLC010956]

Regd. Office: Office No. 904, 9th Floor, Shapath-I Complex, Opp. Rajpath Club, Nr. Madhur Hotel,
S. G. Highway, Bodakdev, Ahmedabad – 380 054, Gujarat, India

E-mail : info@kamronlabs.com



KAMRON

Particulars		3 months ended on			Previous Year ended on 31-03-2019
		30-06-2019	31-03-2019	30-06-2018	
		(Unaudited)	(Audited)	(Unaudited)	
14	Other Comprehensive Income				
	<i>Items that will not be reclassified subsequently to profit or loss</i>		-	-	-
	Income tax relating to items that will not be reclassified to profit or loss		-	-	-
	<i>Items that will be reclassified subsequently to profit or loss</i>		-	-	-
	Income tax relating to items that will be reclassified to profit or loss		-	-	-
	Other Comprehensive Income, net of tax		-	-	-
15	Total Comprehensive Income for the period (13+14)	(60.46)	183.27	0.16	2.76
16	Paid-up equity shares capital (Face Value per share Rs. 10/-)	585.00	585.00	585.00	585.00
17	Reserves excluding Revaluation Reserves				112.84
18	Earnings Per Share of Rs. 10/- each (for continuing operations)				
	- Basic	(1.03)	3.13	-	0.05
	- Diluted	(1.03)	3.13	-	0.05
19	Earnings Per Share of Rs. 10/- each (for discontinued operations)				
	- Basic	(1.03)	-	-	-
	- Diluted	(1.03)	-	-	-
20	Earnings Per Share of Rs. 10/- each (for discontinued & continuing operations)				
	- Basic	(1.03)	3.13	-	0.05
	- Diluted	(1.03)	3.13	-	0.05



FOR, KAMRON LABORATORIES LTD.

Santhosh Lalan
MANAGING DIRECTOR

KAMRON LABORATORIES LIMITED

[CIN : L24231GJ1988PLC010956]

Regd. Office: Office No. 904, 9th Floor, Shapath-I Complex, Opp. Rajpath Club, Nr. Madhur Hotel,
S. G. Highway, Bodakdev, Ahmedabad – 380 054, Gujarat, India

E-mail : info@kamronlabs.com



Notes:

1	The Company is operating only in one segment i.e. Pharma. Hence segment reporting is not given.
2	The Company does not have any subsidiary / associate.
3	Provision for taxation/deferred taxation, if any, will be made at the year end.
4	Figures, wherever required, are regrouped / rearranged.
5	The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 13 th August, 2019



Date: 13th August, 2019.
Place: Ahmedabad

For KAMRON LABORATORIES LIMITED


KAMLESH J. LASKARI
MANAGING DIRECTOR

KAMRON LABORATORIES LIMITED

[CIN : L24231GJ1988PLC010956]

Regd. Office: Office No. 904, 9th Floor, Shapath-I Complex, Opp. Rajpath Club, Nr. Madhur Hotel,
S. G. Highway, Bodakdev, Ahmedabad – 380 054, Gujarat, India

E-mail : info@kamronlabs.com



KAMRON

17th August, 2019

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

Company Code No. 524604

Dear Sirs,

**Sub: Submission of Limited Review Report for Financial Results
for the quarter ended on 30th June, 2019**


We refer to our letter dated 13th August, 2019 enclosing Unaudited Financial Results for the quarter ended on 30th June, 2019.

We are now enclosing herewith Limited Review Report for Unaudited Financial Results for the quarter ended on 30th June, 2019.

This is as per Regulation – 33 of the SEBI (LODR) Regulations, 2015.

Thanking you,

Yours faithfully,
for KAMRON LABORATORIES LIMITED


KAMLESH J. LASKARI
MANAGING DIRECTOR



Encl: As above.

LIMITED REVIEW REPORT**Review Report to the Board of Directors of Kamron Laboratories Limited**

We have reviewed the accompanying statement of unaudited financial results of Kamron Laboratories Limited (Name of the Company) for the period ended 30th June 2019. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



For **RANGWALA & CO**
Chartered Accountants
(Firm's Registration No. 115833W)



(Z.E. RANGWALA)
Partner
(Membership No. 031268)

Place of signature: AHMEDABAD
Date: 17/08/2019

UDIN : 19031268AAAAE1675.